Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma

Exploring novel therapeutic targets of Diffuse large B cell lymphoma (DLBCL) to overcome its resistance to Bruton's Tyrosine Kinase (BTK) inhibitors is a key topic. Lipid metabolism, crucial in the resistance landscape of various cancers, may unlock new aspects of BTK inhibitor resistance in DLBCL. Despite the known importance of lipid metabolism in oncological resistance patterns, its intricate role in DLBCL and its resistance to BTK inhibitor therapies remains largely uncharted. This review will explore the complex relationship between lipid metabolism and BTK inhibitor resistance, giving new insights for improving the effectiveness of BTK inhibitors and developing innovative combination treatment methods for DLBCL. This review holds the potential for guiding future research directions, optimizing existing therapeutic processes, and inspiring the development of innovative combinatorial therapeutic strategies that improve outcomes in patients with DLBCL.